ScholarLens Back to search
2001•European Journal of CancerRequires access

Phase III trial of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (MAYO) vs. weekly oxaliplatin (OXA) plus high dose 24h 5-FU infusion/FA in patients with advanced colorectal cancer (CRC)

Axel F. Grothey, Thomas Buechele, Hendrik Kroening, Karsten Ridwelski, Peter Reichardt, Albrecht Kretzschmar, M.R. Clemens, Hans‐Joachim Schmoll

Open publisher page 57 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 57 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Folinic acid, Oxaliplatin, Fluorouracil, Bolus (digestion), Medicine, Colorectal cancer, Internal medicine, Gastroenterology

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
Phase III trial of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (MAYO) vs. weekly oxaliplatin (OXA) plus high dose 24h 5-FU infusion/FA in patients with advanced colorectal cancer (CRC) — Research Paper | ScholarLens